The effects of transdermal contraception on lipid profiles, carbohydrate metabolism and coagulogram in Thai women

Gynecological Endocrinology

Volumn 26, Issue 5, 2010, Pages 361-365

  Kiriwat, Orawan ^a   Petyim, Somsin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Carbohydrate metabolism; Coagulogram; Contraceptive patch; Lipid profile

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD CLOTTING; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CONTRACEPTION; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; THAILAND; TRANSDERMAL CONTRACEPTION;

ADMINISTRATION, CUTANEOUS; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BLOOD COAGULATION; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; CHOLESTEROL; CONTRACEPTIVE AGENTS, FEMALE; FASTING; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; PROSPECTIVE STUDIES; THAILAND; TRIGLYCERIDES;

EID: 77951126009     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903511455     Document Type: Article

References (21)

1. Huezo C, Diaz S. Quality of care in family planning: clients' rights and providers' needs. Adv Contracept 1993;9:129-139. (Pubitemid 23254840)
2. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plan Perspect 1999;31:64-72.
3. Burkman RT. The transdermal contraceptive system. Am J Obstet Gynecol 2004;190:S49-S53.
4. Taneepanichskul S. Norelgestromin/ethinyl estradiol transdermal system. J Med Assoc Thai 2005;88:S82-S84.
5. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002;77:S13-S18.
6. Piyasirisilp R, Taneepanichskul S. A clinical study of transdermal contraceptive patch in Thai adolescence women. J Med Assoc Thai 2008;91:137-141. (Pubitemid 351413670)
7. Kiriwat O, Petyim S. Transdermal contraception. Siriraj Med J 2008;60:324-329.
8. Boonyarangkul A, Taneepanichskul S. Comparison of cycle control and side effects between transdermal contraceptive patch and an oral contraceptive in women older than 35 years. J Med Assoc Thai 2007;90:1715-1719. (Pubitemid 350057126)
9. Graziottin A. A review of transdermal hormonal contraception: focus on the ethinylestradiol/norelgestromin contraceptive patch. Treat Endocrinol 2006;5:359-365. (Pubitemid 44788153)
10. Weisberg F, Bouchard C, Moreau M, Audet MC, Mawdsley S, DattaniD,Dinniwell J,HorbayGL.P for andsatisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. J Obstet Gynaecol Can 2005;27:350-359.
11. Archer DF, Bigrigg A, Smallwood GH, Shangold GA, Creasy GW, Fisher AC. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002;77:S27-S31.
12. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, Creasy GW. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001;285:2347-2354. (Pubitemid 32424103)
13. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002;77:S19-S26.
14. Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001;98:799-805.
15. Creasy GW, Fisher AC, Hall N, Shangold GA. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. J Reprod Med 2003;48:179-186.
16. Deveneni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol 2007;47:497-509.
17. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109:339-346.
18. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microgram of ethinyl estradiol. Contraception 2006;73: 223-228.
19. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microgram of ethinyl estradiol. Contraception 2007;76:4-7.
20. Worralurt C, Taneepanichskul S. Risk factors of venous thromboembolism (VTE) in Thai reproductive aged female: King Chulalongkorn Memorial Hospital experience. J Med Assoc Thai 2005;88:1502-1505.
21. Angchaisuksiri P, Atichartakarn V, Aryurachai K, Archararit N, Rachakom B, Atamasirikul K, Tiraganjana A. Risk factors of venous thromboembolism in thai patients. Int J Hematol 2007;86:397-402.